NEW YORK, October 23, 2017 /PRNewswire/ --
If you want a Stock Review on JAGX, KTOV, MBVX, or MRTX then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's focus was on the Biotech industry, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies
San Francisco, California-based Jaguar Health Inc.'s shares rose 1.08%, finishing last Friday's session at $0.19. A total volume of 1.42 million shares was traded. The stock is trading below its 50-day moving average by 47.15%. Additionally, shares of Jaguar Health, which focuses on developing and commercializing novel gastrointestinal prescription products from plants, have a Relative Strength Index (RSI) of 33.98.
On October 19th, 2017, Jaguar Health announced that its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has established a scientific advisory board for each potential follow-on indication currently planned for Mytesi® (crofelemer), Napo's FDA-approved, first-in-class anti-secretory human prescription drug. Additionally, Jaguar announced that Dr. Lee Schwartzberg, MD, FACP, a nationally-recognized medical oncologist and hematologist, has joined Napo's scientific advisory board for cancer therapy-related diarrhea. Your complete research report on JAGX can be retrieved for free at:
Kitov Pharmaceuticals Holdings
On Friday, shares in Jerusalem, Israel-based Kitov Pharmaceuticals Holdings Ltd ended the session 2.07% lower at $2.37. The stock recorded a trading volume of 145,920 shares. The Company's shares have surged 22.80% in the last month and 21.54% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 18.53% and 16.17%, respectively. Moreover, shares of Kitov Pharma, which engages in developing non-steroidal anti-inflammatory drugs that treat the pain of osteoarthritis without causing cardiovascular problems, have an RSI of 53.93.
On October 06th, 2017, Kitov Pharma (KTOV) announced the acquisition of an additional 27% stake in TyrNovo Ltd, a privately held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders. As announced on January 13th, 2017, KTOV had acquired a controlling interest, which is now approximately 65%, of TyrNovo. After the closing of this transaction, KTOV will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares. A free report on KTOV is just a click away at:
MabVax Therapeutics Holdings
San Diego, California-based MabVax Therapeutics Holdings Inc.'s stock dropped 4.01%, to close the day at $0.71 with a total trading volume of 287,311 shares. The stock is trading 16.93% above their 50-day moving average. Shares of the Company, which discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers, have an RSI of 54.29.
On October 11th, 2017, MabVax Therapeutics announced the initiation of patient enrollment at a second site, Memorial Sloan Kettering Cancer Center, in a Phase 1 clinical trial evaluating a new radioimmunotherapy product for patients with locally advanced or metastatic adenocarcinoma of the pancreas or other CA19-9 positive malignancies, including colon and lung cancers. MVT-1075 combines a potent radiotherapy with the tumor targeting specificity of the HuMab-5B1 antibody. Sign up for your complimentary research report on MBVX at:
Shares in San Diego, California headquartered Mirati Therapeutics Inc. recorded a trading volume of 647,088 shares. The stock ended at $15.75, rising 1.29% from the last trading session. The Company's shares have skyrocketed 52.17% in the past month, 218.18% over the previous three months, and 231.58% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 76.88% and 177.62%, respectively. Furthermore, shares of Mirati Therapeutics, which develops a pipeline of oncology products, have an RSI of 75.64.
On October 12th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $20 per share.
On October 12th, 2017, Mirati Therapeutics announced that it has been included in the SU2C Catalyst[TM] program, a cutting-edge research initiative, led by Stand Up To Cancer (SU2C) designed to bring innovative cancer treatments to patients quickly through novel collaborations between industry and academia. Register for free on DailyStockTracker.com and download the latest research report on MRTX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Azotemia is a condition characterized by high blood nitrogen levels, leading to acute renal ...
Nipah virus infection has emerged recently and can cause severe disease in both animals and humans ...
Donating blood is a life-saving act. Consider increasing your iron intake before and after you ...View All